Maternal COVID-19 Vaccine May Reduce the Risk of MIS-C in Infants: A Narrative Review

Area of Science:

• Pediatric infectious diseases
• Maternal and child health
• Immunology

Background:

• COVID-19 infection in children typically causes mild illness, but Multi-organ Inflammatory Syndrome (MIS-C) is a rare, serious complication.
• MIS-C can occur in neonates, typically 2-4 weeks post-infection or exposure.
• COVID-19 vaccination is approved for children 6 months+ and recommended during pregnancy, showing reduced MIS-C risk in vaccinated children.

Purpose of the Study:

• To review existing literature and hypothesize that maternal COVID-19 vaccination can reduce the risk and severity of MIS-C in infants.
• To explore the protective mechanisms of maternal vaccination against infant MIS-C.

Main Methods:

• Literature review of studies on COVID-19 in pediatric populations.
• Analysis of data on MIS-C prevalence in vaccinated versus unvaccinated children.
• Examination of evidence for passive antibody transfer from maternal vaccination to infants.

Main Results:

• Maternal COVID-19 vaccination during pregnancy is associated with anti-spike protein antibodies in infants, persisting for at least 6 months.
• Completion of a 2-dose mRNA COVID-19 vaccine series during pregnancy reduced infant hospitalization risk.
• Vaccinated children show a significantly lower prevalence and risk of MIS-C complications.

Conclusions:

• Maternal COVID-19 vaccination is safe and recommended, offering protection against severe maternal and infant outcomes.
• Evidence supports the hypothesis that maternal vaccination can confer protection to infants against MIS-C.
• Further research is warranted to confirm the protective effect of maternal COVID-19 vaccination on infant MIS-C.